Fatty Acid Binding Protein Antibody Sampler Kit #62511
Product Information
Kit Usage Information
Protocols
- 7074: Western Blotting
- 7076: Western Blotting
- 13347: Western Blotting, Immunofluorescence
- 13368: Western Blotting, Immunofluorescence, Immunofluorescence
- 14780: Western Blotting, Immunoprecipitation (Magnetic)
- 39926: Western Blotting, Immunohistochemistry (Paraffin)
- 50699: Western Blotting
Product Description
Background
Fatty acid binding protein 3 (FABP3) is predominantly expressed in heart, skeletal muscle, brain, and mammary gland (4). FABP3 may play a role in supplying energy to the heart and other tissues (5). The release of FABP3 from the heart upon infarction is used as a serum marker for myocardial stress and cardiotoxicity (6). Additional studies suggest that FABP3 is a potential tumor suppressor in breast cancer (7).
The predominant FABP found in adipocytes is fatty acid binding protein 4 (FABP4), also called adipocyte fatty acid binding protein or aP2. FABP4 is also expressed in macrophages (8). FABP4 knockout mice fed a high-fat and high-calorie diet become obese but develop neither insulin resistance nor diabetes, suggesting that this protein might be a link between obesity and insulin resistance and diabetes (9). Mice deficient in both FABP4 and ApoE show protection against atherosclerosis compared to those deficient only in ApoE (8). Mice carrying a FABP4 genetic variant exhibit both reduced FABP4 expression and a reduced potential for developing type 2 diabetes and coronary heart disease. A related study in humans indicated a similar pattern, suggesting that FABP4 may be a potential therapeutic target in the treatment of these disorders (1).
Fatty acid binding protein 5 (FABP5) is known as the epidermal FABP, as it was originally identified in studies on psoriasis (10), where it was shown to play a role in keratinocyte differentiation (11). It has since been found to play diverse roles in other normal physiological processes as well as in disease states (12).
Fatty acid binding protein 7 (FABP7) is abundantly expressed in fetal brain and may be essential for development (13). Expression is required for the establishment of the radial glial fiber system, a system necessary for cortical layer development (14). Increased FABP7 expression is associated with reduced survival in patients with glioblastoma (15) and is also found in glial cells following nerve injury (16). Investigators have found that loss of FABP7 may be involved in breast cancer development and progression, and FABP7 expression has been shown to induce mammary differentiation and inhibit breast cancer cell growth (17,18).
- Tuncman, G. et al. (2006) Proc Natl Acad Sci U S A 103, 6970-5.
- Haunerland, N.H. and Spener, F. (2004) Prog Lipid Res 43, 328-49.
- Mansego, M.L. et al. (2012) PLoS One 7, e31853.
- Heuckeroth, R.O. et al. (1987) J Biol Chem 262, 9709-17.
- Binas, B. et al. (1999) FASEB J 13, 805-12.
- Lippi, G. et al. (2013) Clin Biochem 46, 26-30.
- Nevo, J. et al. (2010) Oncogene 29, 6452-63.
- Makowski, L. et al. (2001) Nat Med 7, 699-705.
- Hotamisligil, G.S. et al. (1996) Science 274, 1377-9.
- Madsen, P. et al. (1992) J Invest Dermatol 99, 299-305.
- Siegenthaler, G. et al. (1994) Biochem J 302 (Pt 2), 363-71.
- Thumser, A.E. et al. (2014) Curr Opin Clin Nutr Metab Care 17, 124-9.
- Shimizu, F. et al. (1997) Biochim Biophys Acta 1354, 24-8.
- Feng, L. and Heintz, N. (1995) Development 121, 1719-30.
- Liang, Y. et al. (2005) Proc Natl Acad Sci U S A 102, 5814-9.
- Miller, S.J. et al. (2003) Mol Cell Biol 23, 2213-24.
- Shi, Y.E. et al. (1997) Cancer Res 57, 3084-91.
- Wang, M. et al. (2000) Cancer Res 60, 6482-7.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.